About: Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections
Creator	Liu, Jiangning Qin, Chuan Xu, Yanfeng Wu, Jing Liu, Yongdong Xue, Ling Zhao, Binbin
Source	PMC
abstract	BACKGROUND: Prophylactic vaccines are critical in preventing hand, foot, and mouth disease (HFMD) primarily caused by human enterovirus 71 (EV71) infection. Children aged less than 5 years are especially susceptible to EV71 infections. In addition to the development of vaccines containing the inactivated virus, those containing virus-like particles (VLPs) with repeated antigens also constitute an effective preventive strategy for EV71 infections, with safety and productivity advantages. We previously developed a fusion protein composed with truncated peptides of the EV71 capsid protein, which assembled into spherical particles. This study aimed to assess the immunoprotective effects of this fusion protein as a vaccine candidate in a mouse model of EV71 infection. METHODS: To evaluate the protective effect of fusion protein vaccine candidate, neonatal mice born by immunized female mice, as well as normal neonatal mice immunized twice were infected with EV71 virus. Whereafter, the survival rates, clinical scores and viral loads were measured. RESULTS: The high dosage and booster immunization helped induce specific serum antibodies with high neutralization titers, which were transferred to neonatal mice, thereby facilitating effective resistance towards EV71 infection. An active immune response was also observed in neonatal mice which generated following immunization. CONCLUSIONS: The present results suggest that this fusion protein is a suitable vaccine candidate in treating EV71 infections.
has issue date	2020-04-22(xsd:dateTime)
bibo:doi	10.1186/s12985-020-01328-8
bibo:pmid	32321526
has license	cc-by
sha1sum (hex)	8a7750539981af35bced41e47799c28d648bf8fa
schema:url	https://doi.org/10.1186/s12985-020-01328-8
resource representing a document's title	Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections
has PubMed Central identifier	PMC7178760
has PubMed identifier	32321526
schema:publication	Virol J
resource representing a document's body	covid:8a7750539981af35bced41e47799c28d648bf8fa#body_text
is schema:about of	named entity 'born' named entity 'productivity' named entity 'measured' named entity 'dosage' named entity 'vaccine' named entity 'infections' named entity 'enterovirus' named entity 'ADDITION' named entity 'CONCLUSIONS' named entity 'HUMAN ENTEROVIRUS 71' named entity 'RESULTS' named entity 'IMMUNOPROTECTIVE' named entity 'NEUTRALIZATION' named entity 'HIGH' named entity 'REPEATED' named entity 'BACKGROUND' named entity 'FUSION PROTEIN' named entity 'CRITICAL' named entity 'VIRUS-LIKE PARTICLES' named entity 'AGED' named entity 'susceptible' named entity 'mouse' named entity 'spherical' named entity 'neonatal' named entity 'Prophylactic' named entity 'advantages' named entity 'resistance' named entity 'development' named entity 'mice' named entity 'enterovirus' named entity 'candidate' named entity 'peptides' named entity 'neonatal' named entity 'mice' named entity 'survival rates' named entity 'neonatal' named entity 'fusion protein' named entity 'Prophylactic' named entity 'immunization' named entity 'mice' named entity 'mice' named entity 'HFMD' named entity 'mouse model' named entity 'fusion protein' named entity 'enterovirus 71' named entity 'virus' named entity 'vaccine' named entity 'statistically significant' named entity 'vaccine' named entity 'EV71' named entity 'fusion protein' named entity '2.0' named entity 'immunization' named entity 'cross-reactivity' named entity 'peptide' named entity 'monovalent' named entity 'mouse model' named entity 'disease outbreaks' named entity 'EV71' named entity 'antigens' named entity 'viruses' named entity 'herpangina' named entity 'Germany' named entity 'disease prevention' named entity 'viruses' named entity 'Sarawak' named entity 'cross-reactivity' named entity 'neurological diseases' named entity 'N-terminal' named entity 'NaOH' named entity 'VLPs' named entity 'neutralizing antibody' named entity 'viral capsid' named entity 'immunohistochemical staining' named entity 'Glycine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software